Vascular Solutions Inc. (VASC) Jumps 6.71% on January 29

Equities Staff |

Vascular Solutions Inc. (VASC) was among the biggest gainers on the Russell 2000 for Friday January 29 as the stock popped 6.71% to $27.05, representing a gain of $1.7 per share. Some 108,224 shares traded hands on 1,112 trades, compared with an average daily volume of 110,718 shares out of a total float of 17.36 million. The stock opened at $25.46 and traded with an intraday range of $27.11 to $25.46.

After today's gains, Vascular Solutions Inc. reached a market cap of $469.5 million. Vascular Solutions Inc. has had a trading range between $40.33 and $24.58 over the last year, and it had a 50-day SMA of $32.69 and a 200-day SMA of $33.82.

The stock has a P/E Ratio of 47.

Vascular Solutions Inc is a medical device company. It is engaged in providing solutions to interventional cardiologists and interventional radiologists.

Vascular Solutions Inc. is based out of Minneapolis, MN and has some 568 employees. Its CEO is Howard Root.

For a complete fundamental analysis analysis of Vascular Solutions Inc., check out Equities.com’s Stock Valuation Analysis report for VASC. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

Ozobot by Evollve Inc

Ozobot is a world leader in compact super intelligent robots that entertain and educate through fun interactive gaming.

BioSculpture Technology, Inc.

BioSculpture Technology, Inc. (“BST”) is a commercial-stage medical device manufacturer of liposuction surgical instruments for surgeons. It offers the FDA-cleared Twin Cannula Assisted Liposuction ("TCAL") Airbrush Liposculptor II® controllers, Airbrush®…